201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC). (December 2022) - Jerusalem, G.; De Braud, F.G.M.; de Jonge, M.J.A.; Grell, P.; Gonçalves, A.; Tan, T.J.Y.; Greil, R.; Yap, T.A.; Lin, C-C.; Kornbluth, K.A.; Yang, X.; Vong, C.; et al.